Abstract: The present disclosure belongs to the technical field of biomedicine, and specifically relates to use of a malic enzyme 1 (ME1) inhibitor in preparation of a drug for preventing and treating pulmonary hypertension (PH) and as a marker for detecting and/or treating the PH. Since a protein level and/or an enzymatic activity are significantly increased in a lung tissue, the ME1 can be used as a marker for detecting or treating the PH. Meanwhile, the ME1 inhibitor can ameliorate pulmonary vascular resistance (PVR) and right ventricular involvement/right heart failure in PH patients by reducing a right ventricular systolic pressure (RVSP) and a right ventricular hypertrophy index (RVHI). Therefore, the ME1 inhibitor can be used as a therapeutic target for treating the PH, thereby increasing a medical utility of the ME1 and the ME1 inhibitor.

Abstract: The present disclosure provides use of malic enzyme 2 (ME2) in preparation of a diagnostic reagent or a medicament for silicosis or pulmonary fibrosis-related diseases, and belongs to the technical fields of medical treatment and medicine. Research results of the present disclosure show that ME2 knockout significantly alleviates inflammatory response and fibrotic lesions in mice with silicosis. Based on the above research results, the present disclosure provides use of ME2 in treatment of pulmonary inflammatory responses and pulmonary fibrotic lesions of silicosis or pulmonary fibrosis-related diseases. Expression of ME2 is inhibited to alleviate the inflammatory response and fibrotic lesions of the silicosis, providing support for exploring a targeted drug for treating pulmonary inflammatory responses and pulmonary fibrosis of silicosis or pulmonary fibrosis-related diseases.

Abstract: The present disclosure provides use of an Fc?RIII inhibitor for treating pulmonary fibrosis, and belongs to the technical field of biomedicine. Results indicate that Fc?RIII mediates macrophage phagocytosis of silica particles, Fc?RIII knockout can effectively relieve pulmonary inflammatory response and fibrotic lesions in mice with silicosis, and further intratracheal administration of an anti-Fc?RIII antibody significantly delays disease progression of mice at fibrosis phase. Therefore, the present disclosure first sets forth that the Fc?RIII inhibitors can be used for treating pulmonary fibrosis, which is of importance to the screening of new drugs and provides a new idea for treatment of pulmonary fibrosis.